Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$4.87 +0.08 (+1.67%)
As of 05/25/2026 03:59 PM Eastern
Compare

BCT vs. HBP, SCYB, COM, NVH, and IGX

Should you buy BriaCell Therapeutics stock or one of its competitors? MarketBeat compares BriaCell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BriaCell Therapeutics include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Helix BioPharma?

BriaCell Therapeutics (TSE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

BriaCell Therapeutics has a beta of 1.947765, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.403644, suggesting that its share price is 60% less volatile than the broader market.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Neutral

0.1% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Helix BioPharma's return on equity of -36.79% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -166.26% -122.71%
Helix BioPharma N/A -36.79%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
BriaCell Therapeutics N/A -166.26%-122.71%

0.1% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
BriaCell Therapeutics Neutral

Summary

Scythian Biosciences and BriaCell Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, 138267 (COM.TO)'s average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
BriaCell Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
BriaCell Therapeutics N/A -166.26%-122.71%

Summary

138267 (COM.TO) and BriaCell Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BriaCell Therapeutics has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
BriaCell Therapeutics N/A -166.26%-122.71%

In the previous week, Novoheart's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
BriaCell Therapeutics Neutral

Summary

Novoheart and BriaCell Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to IntelGenx Technologies?

BriaCell Therapeutics (TSE:BCT) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

BriaCell Therapeutics has higher earnings, but lower revenue than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A

IntelGenx Technologies' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -166.26% -122.71%
IntelGenx Technologies N/A N/A N/A

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled IntelGenx Technologies'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
IntelGenx Technologies Neutral

Summary

BriaCell Therapeutics and IntelGenx Technologies tied by winning 4 of the 8 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$35.31MC$477.13MC$6.46BC$12.16B
Dividend Yield13.70%3.87%2.76%6.20%
P/E Ratio-0.343.8121.2237.64
Price / SalesN/A7,288.62553.9211.68
Price / CashN/A13.1343.4982.29
Price / Book0.4584.7810.374.50
Net Income-C$2.37M-C$96.07MC$3.57BC$299.09M
7 Day Performance0.83%0.04%6.40%2.48%
1 Month Performance-8.11%0.56%3.52%1.47%
1 Year Performance-89.03%63.39%34.02%53.55%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$4.87
+1.7%		N/A-88.5%C$35.31MN/AN/A16
HBP
Helix BioPharma
N/AC$1.58
flat		N/AN/AC$120.68MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel